Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Biogen To Restructure | Contract Pharma

What are you searching for?

Sign in
Breaking News

Biogen To Restructure

Biogen Idec has announced plans to restructure, and will consolidate facilities and cease development of certain research projects in an effort to cut costs and focus on its most promising programs.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Biogen Idec has announced plans to restructure, and will consolidate facilities and cease development of certain research projects in an effort to cut costs and focus on its most promising programs.

George Scangos, the company’s recently appointed chief executive officer, commented at his appointment that he “planned to instill a sense of urgency in every aspect of the business to ensure that we execute at the highest levels and capitalize on our growth opportunities.”

Biogen’s multiple sclerosis drugs Avonex and Tysabri face increased competition from new products in development. Tysabri has also been associated with safety problems. Biogen is currently developing a test to screen patients at risk of developing the potentially deadly brain infection, PML. Biogen markets Tysabri in collaboration with Elan Corp.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters